Ipilimumab

Ipilimumab  is a new drug that is expected to be approved by the FDA as early as this year.  It's use has almost doubled the average of the survival rate of people with stage III or IV melanoma.  It has many side effects which are mild in most people, but if it works they are probably worth it.